Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers

[1]  Lei Cao,et al.  Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer , 2021, Frontiers in Oncology.

[2]  H. Gevensleben,et al.  Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial , 2020, The Lancet. Oncology.

[3]  A. Drilon,et al.  Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[4]  A. Mansfield,et al.  Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. , 2020, Journal of Clinical Oncology.

[5]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[6]  Nefedov Ao,et al.  Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability? , 2020 .

[7]  Su Jin Lee,et al.  Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers , 2020, Journal of oncology.

[8]  X. Yi,et al.  Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer , 2020, International journal of cancer.

[9]  P. A. Futreal,et al.  The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma , 2019, Clinical Cancer Research.

[10]  A. Rappa,et al.  Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis , 2019, Journal of Clinical Pathology.

[11]  Chun Xing Li,et al.  Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer , 2019, Theranostics.

[12]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[13]  J. Briceño-Delgado,et al.  Colorectal peritoneal metastases: Optimal management review , 2019, World journal of gastroenterology.

[14]  Tong-fu Yu,et al.  Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study , 2019, Front. Oncol..

[15]  P. A. Futreal,et al.  Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS , 2019, Modern Pathology.

[16]  Jia Wei,et al.  Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient , 2018, Cancer biology & therapy.

[17]  Milić Medenica,et al.  Pleural Effusions in Lung Cancer: Detection and Treatment , 2018, Lung Cancer - Strategies for Diagnosis and Treatment.

[18]  P. Sugarbaker.  Gastric cancer: prevention and treatment of peritoneal metastases , 2018 .

[19]  X. Yi,et al.  Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA. , 2017, The Journal of molecular diagnostics : JMD.

[20]  Jia Wei,et al.  Peritoneal metastasis in relation to outcome and therapeutic strategy in gastric cancer , 2017 .

[21]  E. Fung,et al.  Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology , 2017, Molecular Cancer Therapeutics.

[22]  James X. Sun,et al.  Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target , 2016, Clinical Cancer Research.

[23]  R. Shoemaker,et al.  Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer , 2015, British Journal of Cancer.

[24]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[25]  V. Velculescu,et al.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. , 2014, Cancer discovery.

[26]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[27]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[28]  Jason Li,et al.  CONTRA: copy number analysis for targeted resequencing , 2012, Bioinform..